These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18209648)

  • 1. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
    Aristodemou P; Baer R
    Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
    Tomsak RL; Zaret CR; Weidenthal D
    Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
    [No Abstract]   [Full Text] [Related]  

  • 4. Dermatological side effects of brimonidine: a report of three cases.
    Sodhi PK; Verma L; Ratan J
    J Dermatol; 2003 Sep; 30(9):697-700. PubMed ID: 14578562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced ectropion: what is best practice?
    Hegde V; Robinson R; Dean F; Mulvihill HA; Ahluwalia H
    Ophthalmology; 2007 Feb; 114(2):362-6. PubMed ID: 17270684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent central nervous system depression in infants after the use of topical brimonidine.
    Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
    Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anterior uveitis as a side effect of topical brimonidine.
    Byles DB; Frith P; Salmon JF
    Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
    Watts P; Hawksworth N
    Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic side effects of ophthalmic drops.
    Levy Y; Zadok D
    Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
    Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma.
    Walters G; Taylor RH
    Eye (Lond); 1999 Dec; 13 ( Pt 6)():797-8. PubMed ID: 10707152
    [No Abstract]   [Full Text] [Related]  

  • 14. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
    Bowman RJ; Cope J; Nischal KK
    Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible cicatricial ectropion associated with EGFR inhibitors.
    Scofield-Kaplan S; Todaro J; Winn BJ
    Orbit; 2018 Oct; 37(5):364-367. PubMed ID: 29336655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A paradoxical ocular effect of brimonidine.
    Mushtaq B; Sardar J; Matthews TD
    Am J Ophthalmol; 2003 Jan; 135(1):102-3. PubMed ID: 12504711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The teardrop sign: a rare dermatological reaction to brimonidine.
    Scruggs JT; Whiteside-Michel J; Brodsky MC
    Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract]   [Full Text] [Related]  

  • 20. Brimonidine and pupillary diameter.
    Mastropasqua L; Carpineto P; Ciancaglini M
    Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.